Protective effects of captopril in diabetic rats exposed to ischemia/reperfusion renal injury

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 2, 2013, Pages 243-252

  Fouad, Amr A ^a   Al Mulhim, Abdulruhman S ^a   Jresat, Iyad ^a   Morsy, Mohamed A ^a  

^a KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

captopril; diabetes mellitus; ischaemia reperfusion; kidney; rats

Indexed keywords

ALDOSTERONE; CAPTOPRIL; CASPASE 3; CREATININE; FAS LIGAND; GLUCOSE; GLUTATHIONE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; MALONALDEHYDE; NITRIC OXIDE; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPOINSULINEMIA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; KIDNEY INJURY; KIDNEY ISCHEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; RISK REDUCTION; UPREGULATION;

EID: 84871712489     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01585.x     Document Type: Article

References (56)

1. Edelstein CL, et al,. The nature of renal cell injury. Kidney Int 1997; 51: 1341-1351.
2. Kuramochi G, Homma S,. Postischemic recovery process of renal oxygen consumption after ischemia in normal and streptozotocin diabetic rats. Nephron 1993; 64: 436-442.
3. Goor Y, et al,. Nitric oxide in ischemic acute renal failure of streptozotocin diabetic rats. Diabetologia 1996; 39: 1036-1040.
4. Melin J, et al,. Hyperglycemia and renal ischemia-reperfusion injury. Nephrol Dial Transplant 2003; 18: 460-462.
5. Melin J, et al,. Ischemia causes rapidly progressive nephropathy in the diabetic rat. Kidney Int 1997; 52: 985-991.
6. Woodrow G, et al,. Acute renal failure in patients with type 1 diabetes mellitus. Postgrad Med J 1994; 70: 192-194.
7. Ishani A, et al,. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
8. Kurcer Z, et al,. Protective effects of chronic melatonin treatment against renal ischemia/reperfusion injury in streptozotocin induced diabetic rats. Exp Clin Endocrinol Diabetes 2007; 115: 365-371.
9. Vaghasiya J, et al,. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul Pept 2011; 166: 48-54.
10. Wolf G,. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000; 15: 61-63.
11. Scribner AW, et al,. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003; 482: 95-99.
12. Liu Y, et al,. Impairment of endothelium-dependent relaxation of rat aortas by homocysteine thiolactone and attenuation by captopril. J Cardiovasc Pharmacol 2007; 50: 155-161.
13. Bolterman RJ, et al,. Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats. Hypertension 2005; 46: 943-947.
14. Ibrahim MA, et al,. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009; 60: 373-381.
15. Amirshahrokhi K, et al,. Effect of captopril on TNF-α and IL-10 in the livers of bile duct ligated rats. Iran J Immunol 2010; 7: 247-251.
16. Scheen AJ,. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30: 487-496.
17. Aminorroaya A, et al,. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 2005; 99: c73-c77.
18. Sharma R, et al,. Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes. Front Biosci 2006; 11: 968-976.
19. Huang Z, et al,. Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats. Clin Sci (Lond) 2008; 115: 35-42.
20. Masiello P, et al,. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998; 47: 224-229.
21. Villa E, et al,. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997; 10: 275-281.
22. Neto JS, et al,. Protection of transplant-induced renal ischemia-reperfusion injury with carbon monoxide. Am J Physiol Renal Physiol 2004; 287: F979-F989.
23. Li Volti G, et al,. Pharmacological induction of heme oxygenase-1 inhibits iNOS and oxidative stress in renal ischemia-reperfusion injury. Transplant Proc 2007; 39: 2986-2991.
24. Clancy RM, Abramson SB,. Nitric oxide: a novel mediator of inflammation. Proc Soc Exp Biol Med 1995; 210: 93-101.
25. Hasegawa G, et al,. Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male spontaneously diabetic Torii rats. Eur J Pharmacol 2009; 605: 164-169.
26. Cai H, et al,. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471-478.
27. Hayashi T, et al,. Impact of the renin-angiotensin-aldosterone system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol 2010; 8: 189-197.
28. Saitoh Y, et al,. Candesartan attenuates fatty acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Res Clin Pract 2010; 90: 54-59.
29. Yuan L, et al,. Effects of renin-angiotensin system blockade on islet function in diabetic rats. J Endocrinol Invest 2010; 33: 13-19.
30. Leung PS,. Pancreatic RAS. Adv Exp Med Biol 2010; 690: 89-105.
31. Luther JM, et al,. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 2011; 54: 2152-2163.
32. Mejia-Vilet JM, et al,. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 2007; 293: F78-F86.
33. Ramirez V, et al,. Adrenalectomy prevents renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2009; 297: F932-F942.
34. Cámara-Lemarroy CR, et al,. Effect of sulfasalazine on renal ischemia/reperfusion injury in rats. Ren Fail 2009; 31: 822-828.
35. Liu WJ, et al,. Notoginsenoside R1 attenuates renal ischemia-reperfusion injury in rats. Shock 2010; 34: 314-320.
36. Ilieva I, et al,. Captopril suppresses inflammation in endotoxin-induced uveitis in rats. Exp Eye Res 2006; 83: 651-657.
37. He X, et al,. Angiotensin-converting enzyme inhibitor captopril prevents oleic acid-induced severe acute lung injury in rats. Shock 2007; 28: 106-111.
38. Jo SK, et al,. alpha-MSH decreases apoptosis in ischaemic acute renal failure in rats: possible mechanism of this beneficial effect. Nephrol Dial Transplant 2001; 16: 1583-1591.
39. Du C, et al,. Increasing resistance of tubular epithelial cells to apoptosis by shRNA therapy ameliorates renal ischemia-reperfusion injury. Am J Transplant 2006; 6: 2256-2267.
40. Shetty S, et al,. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 2002; 7: 413-420.
41. Pedreañez A, et al,. Melatonin decreases apoptosis and expression of apoptosis-associated proteins in acute puromycin aminonucleoside nephrosis. Nephrol Dial Transplant 2004; 19: 1098-1105.
42. Altieri DC,. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006; 18: 609-615.
43. Ouhtit A, et al,. Survivin is not only a death encounter but also a survival protein for invading tumor cells. Front Biosci 2007; 12: 1260-1270.
44. Li JY, et al,. Protective effect of ischemic preconditioning on hepatic ischemia-reperfusion injury by advancing the expressive phase of survivin in rats. Hepatobiliary Pancreat Dis Int 2008; 7: 615-620.
45. Paller MS, et al,. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 1984; 74: 1156-1164.
46. Bian K, et al,. The nature of heme/iron-induced protein tyrosine nitration. Proc Natl Acad Sci U S A 2003; 100: 5712-5717.
47. He X, et al,. Preconditioning with hyperbaric oxygen induces tolerance against renal ischemia-reperfusion injury via increased expression of heme oxygenase-1. J Surg Res 2011; 170: e271-e277.
48. Wang GG, et al,. Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats. Evid Based Complement Alternat Med 2011; 2011: 323171.
49. Bulger EM, et al,. Induction of heme-oxygenase 1 inhibits endothelial cell activation by endotoxin and oxidant stress. Surgery 2003; 134: 146-152.
50. Wen T, et al,. Upregulation of heme oxygenase-1 with hemin prevents d-galactosamine and lipopolysaccharide-induced acute hepatic injury in rats. Toxicology 2007; 237: 184-193.
51. Stocker R, et al,. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-1045.
52. Baranano DE, et al,. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A 2002; 99: 16093-16098.
53. Ollinger R, et al,. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid Redox Signal 2007; 9: 2175-2185.
54. Florczyk UM, et al,. Biliverdin reductase: new features of an old enzyme and its therapeutic significance. Pharmacol Rep 2008; 60: 38-48.
55. Hill-Kapturczak N, Agarwal A,. Carbon monoxide: from silent killer to potential remedy. Am J Physiol Renal Physiol 2006; 290: F787-F788.
56. Vera T, et al,. Protective effect of carbon monoxide-releasing compounds in ischemia-induced acute renal failure. J Am Soc Nephrol 2005; 16: 950-958.